Rhythm Pharmaceuticals posts Phase 2 results for bivamelagon in hypothalamic obesity
Trial record shows completed study testing oral bivamelagon in patients with hypothalamic obesity, with results posted after a 52-week open-label extension.
Rhythm Pharmaceuticals had one trial update of note for the week ending October 30, 2026.
- The Phase 2 study of bivamelagon (also known as LB54640) in hypothalamic obesity is listed as completed, with results first posted on 2026-10-30. The trial evaluated the effect of bivamelagon on safety, weight reduction, and hunger in participants 12 years of age and older with HO, who took oral daily doses of bivamelagon or placebo through Week 14, with eligible participants continuing on bivamelagon through Week 52.1 The study enrolled 28 participants.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.